Phase 2 Parkinson's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with Parkinson's disease using the Movement Disorders Society's official diagnostic criteria at the time of their first study visit
• People whose brain scans (a specialised PET scan using a substance called FEOBV) show low levels of a specific type of nerve signalling in a region at the back of the brain
• People who are either able to give their own informed consent to participate, as confirmed by a specific capacity assessment tool, or who have a legally authorised representative able to co-sign the consent form on their behalf
• People who have mild memory or thinking difficulties that are consistent with a condition called Parkinson's disease Mild Cognitive Impairment (PD-MCI)

Who may not be able to join:

• People who have a Parkinson's-like condition other than Parkinson's disease itself
• People who are currently taking certain dopamine-blocking medications, specific anticholinergic drugs (such as trihexyphenidyl or benztropine), or certain cholinesterase inhibitor medications at the time of their screening visit (confirm with trial site for the full medication list)
• People whose Parkinson's disease severity rates at 4.0 or higher on the Modified Hoehn and Yahr scale at the screening visit, indicating more advanced disease
• People who are currently using, or have used in the past 6 months, any product containing nicotine or nicotine-like (nicotinic) agents, including cigarettes, cigars, pipes, chewing tobacco, e-cigarettes, nicotine patches, nicotine gum, or a medication called varenicline
• People whose brain MRI shows evidence of a stroke affecting both outer and inner brain regions, or a growth in the back part of the brain, that would interfere with analysing the PET scan results
• People for whom an MRI scan is not safe, such as those with a pacemaker, metal fragments near the eyes or spinal cord, or a cochlear implant
• People with severe claustrophobia that would prevent them from undergoing an MRI or PET scan
• People who have reached a limit on their participation in research that involves radiation exposure
• People who are pregnant (a pregnancy test is required within 48 hours of the PET scan for women who could become pregnant) or who are breastfeeding at the time of the screening visit
• People with stage 4 or 5 chronic kidney disease at the time of screening, meaning their kidneys are functioning at a significantly reduced level (confirm with trial site)
• People experiencing a significant and ongoing mood disorder at the time of screening, defined as persistent symptoms of depression or anxiety lasting more than two weeks within the 30 days before signing the consent form, based on self-report
• People showing active thoughts of suicide, as identified by specific questions on a standardised assessment tool called the Columbia Suicide Severity Rating Scale
• People who have had a heart attack or unstable chest pain (unstable angina) in the 90 days before their enrolment visit
• People with a current or past history of epilepsy, or who have had any seizures in the 12 months before their enrolment visit
• People whose self-reported alcohol use scores 8 or higher on a standardised alcohol use assessment tool (the AUDIT) at the time of screening
• People who are unable to swallow pills
• People who have previously had an allergic reaction to a medication called varenicline
• People who are currently taking part in another interventional clinical trial (observational studies are not affected by this criterion)

Important: Always verify eligibility with the trial site directly before applying.